Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    New items announce regulatory status for Libtayo in EU CSCC and a Regeneron oncology update at ESMO, while older items about NB NSCLC survival results and allergy pipeline progress are removed.
    Difference
    100%
    Check dated 2025-10-20T05:37:43.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    Additions introduce high-importance medical research and regulatory news; deletions remove earlier investor conference timing and trial result updates, resulting in a shift toward current clinical news.
    Difference
    100%
    Check dated 2025-10-13T02:51:22.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    Added a major Q3 2025 financial results press release and conference call details; removed a product-labeling FDA update for EYLEA. The page now centers on earnings news rather than the FDA labeling development.
    Difference
    16%
    Check dated 2025-10-05T16:47:21.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Page now emphasizes regulatory/clinical updates (Evkeeza approval for kids; Dupixent CHMP opinion) and removes prior investor/financial disclosures.
    Difference
    100%
    Check dated 2025-09-28T10:11:12.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Additions introduce new high-importance news items (donation, phase 2/3 trial results, rare-disease treatment) and deletions remove older awards and a drug approval plus financial results.
    Difference
    100%
    Check dated 2025-09-21T06:44:21.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    Added two high-impact updates: Libtayo plus chemotherapy shows five-year survival gains in advanced NSCLC, and Regeneron reports two positive Phase 3 allergy trials. Removed older items: donation-matching CSR program and Dupixent BP approval news, shifting the page toward current progress and future pipeline.
    Difference
    100%
    Check dated 2025-09-14T00:20:34.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.